Patent EP-2664919-A1 (EP)
Inventor: SAURAT JEAN HILAIRE
IPC: G01N33/50
Filed: 2012-05-15
Abstract: Sorting substances for the purpose of determining their capacity for sebosuppressive activity in topical skin treatment, an in vivo test involves: choosing a substance from ligands of aryl hydrocarbon receptor (AhR); choosing a mammal expressing cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) gene; treating part of skin of mammal comprising sebaceous glands, with a composition containing substance following a dose/response/response time protocol; examining by immunohistochemical staining expression of CYP1A1 in sebaceous glands of mammal; and selecting substance. Sorting substances for the purpose of determining their capacity for sebosuppressive activity in topical skin treatment, an in vivo test involves: choosing a substance from among the ligands of the aryl hydrocarbon receptor (AhR); choosing a mammal expressing the cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) gene; treating via topical route part of the skin of the mammal comprising sebaceous glands, with a composition containing the substance following a dose/response/response time protocol; examining by immunohistochemical staining the expression of CYP1A1 in sebaceous glands of the part of the skin of the mammal; and selecting the substance as a function of the sequence of onset of immunohistochemical staining in several different types of cells of the sebaceous glands. Independent claims are included for the following: (1) a composition (C1) for treating and/or preventing skin diseases of a human being, particularly acne, seborrheic dermatitis and rosacea, where the composition is configured to treat and/or prevent hyperseborrhea by means of topical application of the composition on a skin, comprising: an active substance selected from AhR agonist ligands having: an ability to activate the AhR receptor; an ability to modulate a gene regulated by AhR; a short half-life in the human organism of 2-96 hours; a measurable positive effect on a recognized criterion of hyperseborrhea, and where the active substance is positively selected by an in vivo test; (2) a pharmaceutical composition (C2) for topical use intended to reduce sebogenesis, containing 5,6-benzoflavone (5,6-BZF) as active substance; and (3) a pharmaceutical composition (C3) for treating and/or preventing human skin diseases, particularly acne, seborrheic dermatitis and rosacea, where the composition is configured to treat and/or prevent hyperseborrhea by means of topical application of the composition on a skin, comprising 5,6-benzoflavone (5,6-BZF) as active substance; (4) topical use of 5,6 benzoflavone (5,6 BZF) and rutecarpine as active substance in a sebosuppressive composition; (5) treating and/or preventing skin diseases of a human being, such as acne, seborrheic dermatitis and rosacea, comprising providing the composition (C1) and administering topically the composition to the human being; and (6) treating and/or preventing hyperseborrhea in a human being, involving providing a composition configured for topical application of a composition on a skin, where the composition contains 5,6 benzoflavone (5,6 BZF) as active substance, and administering topically the composition to the human being. ACTIVITY : Antiseborrheic; Dermatological. No biological data given. MECHANISM OF ACTION : None given.